Macrophages eliminate circulating tumor cells after monoclonal antibody therapy - Wikidata - awgldk - TriplyDB

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

http://www.wikidata.org/entity/Q30569758

about

Influence of immunoglobulin isotype on therapeutic antibody function The emerging molecular machinery and therapeutic targets of metastasis A New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor via Systemic Administration by Taking Advantages of the Limitation of EPR Effect Elucidation of monocyte/macrophage dynamics and function by intravital imaging.Mechanisms of action of therapeutic antibodies for cancer Intravital Microscopy Imaging Approaches for Image-Guided Drug Delivery Systems The Dynamics of Apoptotic Cell Clearance Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodies PEDF increases the tumoricidal activity of macrophages towards prostate cancer cells in vitro.Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high-grade B cell lymphoma.IgG4 can induce an M2-like phenotype in human monocyte-derived macrophages through FcγRI.Macrophages are critical effectors of antibody therapies for cancer Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles.Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy.Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.Heme oxygenase-1 in macrophages controls prostate cancer progression An epitope-specific novel anti-EMMPRIN polyclonal antibody inhibits tumor progression.Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma Targeting Epstein-Barr virus-transformed B lymphoblastoid cells using antibodies with T-cell receptor-like specificities Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.Impact of myeloid-derived suppressor cell on Kupffer cells from mouse livers with hepatocellular carcinoma Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.A constant threat for HIV: Fc-engineering to enhance broadly neutralizing antibody activity for immunotherapy of the acquired immunodeficiency syndrome.Mycobacterium bovis Bacillus Calmette-Guérin Alters Melanoma Microenvironment Favoring Antitumor T Cell Responses and Improving M2 Macrophage Function.bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression.FcγR requirements leading to successful immunotherapy.The multiple facets of FcRn in immunity.Cross-talk between pathogen recognizing Toll-like receptors and immunoglobulin Fc receptors in immunity.The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies.Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.Liver macrophages in healthy and diseased liver.Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB.Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells Effect of trastuzumab interchain disulfide bond cleavage on Fcγ receptor binding and antibody-dependent tumour cell phagocytosis.The role of myeloid cells in cancer therapies.Microenvironmental Effects of Cell Death in Malignant Disease.Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape.Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages.

P2860

Q26772080-40E57412-8408-45F7-8D96-A1DA7F5080D1 Q27022207-A88851AA-B2FE-4F86-93BB-328277FE18B1 Q27300754-6F4C225F-C247-416C-BFCC-D41B49FC1FE5 Q27313900-A9618EFD-FBE0-4E61-880F-1CBC2BDD405F Q28385366-A1F961B8-8D94-4B24-8020-1CE368020949 Q28553638-B1C7F46C-DC99-488A-AC59-9B89061FCE8B Q30276273-382B8A8B-BFBE-40B2-93BF-A0CF12952F7B Q30818421-C23CE5B7-4DB4-408C-8085-3E313257927B Q33558122-35BDD0F4-A8CA-4C2B-ABEF-8C1EC7BC8E49 Q33707941-FEF22040-02AA-4B95-9D57-15D5F1F17BDD Q35597924-21AD3E1D-737E-4409-A19D-A10B5109B08E Q36213225-64015479-C691-4511-9625-540B1A9408B2 Q36213288-7F284185-6FE1-40FC-907C-1A3FFD254F1D Q36327671-003A3B39-B130-422B-9665-88DA4A702D08 Q36401731-CFFB0467-F8F8-4C7E-B110-504A903B0CD3 Q36437030-BF827025-EF71-49F2-9863-8B25086424CA Q36545252-29FB7C4A-1A23-42D2-94AE-8D872EAE4526 Q36710986-8AFBF535-B6D6-4CDC-B1B2-6B88E2594EAC Q36800456-9F84EADA-E2D7-46A1-8B68-A0F9E9915F8B Q37078946-4FE14CA6-DB05-46C5-B133-C0FD4F6BCB07 Q37319382-25D8D08C-0330-4694-B4D5-BBC984111B14 Q37457920-AC3128A1-314A-4154-9564-929C90030CB8 Q37477277-060C6FE3-C33D-4462-B045-A364455D934F Q38542034-694862DD-EEC6-4271-A432-F92EE0E1CBA6 Q38542411-1F5787DF-3012-4A2B-AD5F-548133DD61CB Q38604832-EA75AEB1-8606-452E-B319-EFACCA73BD0E Q38615353-770CD9D0-1BE2-43C3-917D-FE62D50A0634 Q38615360-5DC8114F-8B52-4AC6-989B-5986D3F15C7A Q38615385-B2478F9E-131F-4AE1-9783-1050CC292E2A Q38615394-9070FD27-0762-4FB5-B6FB-E64C4B20C5AC Q38675589-9F94254D-2F93-4D59-85F7-F808C2E4D96D Q38713147-53FB83B8-3089-4BC0-8A1C-204D9953C55C Q38745740-93F60488-FE26-4C12-95AD-C8B1DB47B31D Q38752906-7C598E98-205C-4BF7-8571-9DC20C0FF196 Q38768387-CF52586E-282D-4ECD-9AC7-D93057629D23 Q38845280-D37A9FD5-7E5D-4F14-9482-2D459330AE47 Q38875474-83F3B696-FB06-4115-B936-BEBD2FB838FA Q38936695-5D7A62A4-D3F3-40E9-BD45-7D1C65A102EE Q38958563-CD951888-EE31-4F02-91B0-79DCFFE58F32 Q38970811-9663A160-9759-4BEC-A006-ADB920168C42

P2860

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

http://www.wikidata.org/entity/Q30569758

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

@ast

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

@en

type

label

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

@ast

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

@en

prefLabel

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

@ast

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

@en

P1433

Q30569758-F921D69F-C160-43BC-8146-A0D27067AB8C

P1476

Q30569758-CDAFD347-097B-403E-AD98-FC070A39929A

P2093

Q30569758-0925B975-B79C-4A8A-9B64-C44084F3F85E

Q30569758-1C029EAC-B061-4678-97DA-7E7EA1DDCD96

Q30569758-3BD6C4D8-C910-41DF-95CC-15BC22854D74

Q30569758-69FEE9FD-8164-419D-9266-C0F74A5B7C8B

Q30569758-A9595E5F-8CF7-4C99-9628-346D88F7DF53

Q30569758-AEDF074E-32D4-46CF-84A2-BF0915CD9FE8

Q30569758-B23ED0C5-C19E-490C-91B1-43F558E4A4D1

Q30569758-F98DA0B5-0705-42B9-8A3A-348A277FBAC7

P2860

Q30569758-046CBD71-69BD-471B-9728-8475F860CBB3

Q30569758-097148B6-0EF6-4984-A268-FB3AD07F2D5A

Q30569758-0D90C954-4074-4496-B033-14934D79C8F9

Q30569758-0F12A92D-70DC-43B3-929E-D5B458D411B9

Q30569758-1CB9635B-CC37-492A-AB75-4C8B00450728

Q30569758-20D983BB-B8E7-4BE2-AB0B-D04AB5C95F2E

Q30569758-2F1125B1-4C32-4EBA-A55D-858935D71EF6

Q30569758-37B5AF8D-33D8-4CCD-9C6D-4DCA25490209

Q30569758-3B7BF0C8-BF5B-41A5-9CAD-4DF0F69F834C

Q30569758-3CC3410C-82E2-4758-AFB3-5C232C815720

P304

Q30569758-94F05029-60F8-49A7-AB47-2D87F3223B92

P31

Q30569758-A00D375B-8BE9-4DA0-B107-9C9B888F0041

P356

Q30569758-A3C5664D-9C70-4819-8FBF-7255440B1AB0

P407

Q30569758-F681FD0C-6B40-4A9F-BD45-F955B9A337C5

P433

Q30569758-E4508C0D-859A-4F16-BEED-4DF28274E589

P478

Q30569758-0C8E949F-E35E-4FA3-8E57-D4704C7EBCDB

P50

Q30569758-49547536-977A-4518-BAAB-182FB84F072A

Q30569758-70019AE4-CCA9-4D89-B442-5100283C22CD

P577

Q30569758-8F7DA559-82E6-42AF-BF01-DB15452DC5A4

P5875

Q30569758-5B51CFC1-07C3-4573-AE51-0649E3F316D0

P698

Q30569758-18BDF72B-6E59-4E2F-A121-FE6C99857746

P921

Q30569758-A23B2BF1-83AC-4C8F-9D55-B62D3624A77E

P932

Q30569758-C99C4CE0-2408-48B1-B963-F09071993B55

P356

P1433

Journal of Clinical Investigation

P1476

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

@en

P2093

Kerstin Siegmund

http://www.w3.org/2001/XMLSchema#string

Liane Babes

http://www.w3.org/2001/XMLSchema#string

Marijn Bögels

http://www.w3.org/2001/XMLSchema#string

Nuray Gül

http://www.w3.org/2001/XMLSchema#string

Paul Kubes

http://www.w3.org/2001/XMLSchema#string

Rens Braster

http://www.w3.org/2001/XMLSchema#string

Rianne Korthouwer

http://www.w3.org/2001/XMLSchema#string

Timo L M ten Hagen

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma

Tissue-resident macrophages

Cancer treatment and survivorship statistics, 2012

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Antibody therapy of cancer

FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection

FcgammaRIV: a novel FcR with distinct IgG subclass specificity

Macrophages, innate immunity and cancer: balance, tolerance, and diversity

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma

P304

812-823

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI66776

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

Marjolein van Egmond

Gestur Vidarsson

P577

2014-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259766602

http://www.w3.org/2001/XMLSchema#string

P698

24430180

http://www.w3.org/2001/XMLSchema#string

P921

P932

3904600

http://www.w3.org/2001/XMLSchema#string